

AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Previously presented) A process for producing a dosage form in film form for surface administration of at least one active ingredient and/or nutrient to a living creature comprising at least one active ingredient-containing and/or nutrient-containing layer based on hydrophilic polymers crosslinked with at least one polyacrylic acid derivative by building up individual layers successively on a smooth surface, characterized by the steps:

a) simultaneous spraying of (1) an aqueous solution of the hydrophilic polymers and of the active ingredient and/or of the nutrient and (2) of an aqueous solution of the polyacrylic acid derivative, wherein the aqueous solution of the hydrophilic polymers and of the active ingredient and/or of the nutrient and aqueous solution of the polyacrylic acid derivative are mixed after spraying and the hydrophilic polymers are crosslinked by the polyacrylic acid derivative *in situ*; and
b) removal of the water by drying.

2. (Previously presented) The production process as claimed in claim 1, characterized in that an optionally crosslinked polyacrylic acid is used as polyacrylic acid derivative.

3. (Previously presented) The production process as claimed in claim 1, characterized in that hydroxypropylmethylcellulose, hydroxyethylcellulose and/or methylcellulose is employed as hydrophilic polymer.

4. (Previously presented) The production process as claimed in claim 1, characterized in that the weight ratio of hydrophilic polymers to polyacrylic acid derivative(s) is from 5:1 to 5:4.

5. (Previously presented) A dosage form produced as claimed in claim 1.

6. (Previously presented) The dosage form as claimed in claim 5, characterized in that it has at least one active ingredient-containing and/or nutrient-containing layer, a covering layer and optionally an adhesive layer.

7. (Previously presented) The dosage form as claimed in claim 5, characterized in that at least one active ingredient-containing layer has a concentration gradient of the active ingredient.

8. (Previously presented) The dosage form as claimed in claim 5, characterized in that the covering layer is impermeable for the active ingredient and/or nutrient.

9. (Previously presented) The dosage form as claimed in claim 5, characterized in that the dosage form is covered with a protective layer before application.

10. (Previously presented) The production process as claimed in claim 2, characterized in that the optionally crosslinked polyacrylic acid, is a polyacrylic acid crosslinked with allylsucrose or allylpentaerythritol and/or a polyacrylic acid crosslinked with divinylglycol, optionally neutralized with calcium.

11. (Previously presented) The production process as claimed in claim 10, characterized in that hydroxypropylmethylcellulose is employed as hydrophilic polymer.

12. (Previously presented) The production process as claimed in claim 11, characterized in that the weight ratio of hydrophilic polymers to polyacrylic acid derivative(s) is from 5:2 to 5:3.

13. (Previously presented) The production process as claimed in claim 12, characterized in that the dosage form has a tear strength greater than 40 N.

14. (Previously presented) The dosage form as claimed in claim 5, characterized in that the dosage form has a tear strength greater than 40 N.